LRMR Stock Overview
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Larimar Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.30 |
| 52 Week High | US$13.68 |
| 52 Week Low | US$2.18 |
| Beta | 0.74 |
| 1 Month Change | -12.57% |
| 3 Month Change | 68.20% |
| 1 Year Change | 48.37% |
| 3 Year Change | -32.09% |
| 5 Year Change | n/a |
| Change since IPO | -40.65% |
Recent News & Updates
Recent updates
We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely
Nov 13
Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation
May 19Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth
Feb 02Laramar Therapeutics issued patent for lead pipeline candidate
Oct 20Larimar Therapeutics prices ~$70M stock offering
Sep 14Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?
Sep 02Larimar Therapeutics GAAP EPS of -$0.47
Aug 11We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully
Mar 21Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?
Dec 18Larimar under pressure as FDA puts clinical hold on CTI-1601 program
May 26Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth
Feb 08
Larimar, Avadel, Applied Therapeutics will added to Nasdaq Biotechnology Index
Dec 15Larimar completes dosing in Friedreich’s Ataxia, provides program update
Dec 08Larimar Therapeutics (LRMR) Investor Presentation - Slideshow
Nov 16Larimar Therapeutics reports Q3 results
Nov 10Shareholder Returns
| LRMR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.7% | -4.2% | -3.7% |
| 1Y | 48.4% | -2.0% | 20.5% |
Return vs Industry: LRMR exceeded the US Biotechs industry which returned -1.8% over the past year.
Return vs Market: LRMR exceeded the US Market which returned 20.9% over the past year.
Price Volatility
| LRMR volatility | |
|---|---|
| LRMR Average Weekly Movement | 16.8% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LRMR's share price has been volatile over the past 3 months.
Volatility Over Time: LRMR's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 42 | Carole Ben-Maimon | www.larimartx.com |
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.
Larimar Therapeutics, Inc. Fundamentals Summary
| LRMR fundamental statistics | |
|---|---|
| Market cap | US$461.91m |
| Earnings (TTM) | -US$36.95m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-12.6x
P/E RatioIs LRMR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LRMR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$36.95m |
| Earnings | -US$36.95m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.58 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did LRMR perform over the long term?
See historical performance and comparison